Meeting
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes in metastatic castration-resistant prostate cancer in the up-front treatment era.
Authors
Shunsuke Kamijo
Nagoya University Graduate School of Medicine, Nagoya City, Japan
Shunsuke Kamijo , Yushi Naito , Masashi Kato , Akiyuki Yamamoto , Toyonori Tsuzuki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 336)
DOI
10.1200/JCO.2023.41.6_suppl.336
Abstract #
336
Poster Bd #
L14
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.
First Author: Stephen J. Freedland
Poster
2024 ASCO Annual Meeting
Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.
First Author: Martin W. Schoen
Poster
2022 ASCO Genitourinary Cancers Symposium
Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.
First Author: Elahe A. Mostaghel
Poster
2022 ASCO Genitourinary Cancers Symposium
Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Daniel Joseph Khalaf